Inventor
DESJARLAIS JOHN R
US88 patents
⚠️ This page may combine multiple inventors who share the name “DESJARLAIS JOHN R”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
XENCOR INC
23 patentsUS8367805B2Feb 5, 2013
Fc variants with altered binding to FcRn
XENCOR INC210 citations99
US8039592B2Oct 18, 2011
Optimized Fc variants and methods for their generation
XENCOR INC86 citations99
US7662925B2Feb 16, 2010
Optimized Fc variants and methods for their generation
XENCOR INC349 citations99
US7657380B2Feb 2, 2010
Methods of generating variant antibodies with increased host string content
XENCOR INC169 citations99
US7317091B2Jan 8, 2008
Optimized Fc variants
XENCOR INC872 citations99
US9701759B2Jul 11, 2017
Heterodimeric proteins
XENCOR INC48 citations98
US8383109B2Feb 26, 2013
Optimized Fc variants and methods for their generation
XENCOR INC40 citations98
US10336818B2Jul 2, 2019
Fc variants with altered binding to FcRn
XENCOR INC47 citations97
US9803023B2Oct 31, 2017
Fc variants with altered binding to FcRn
XENCOR INC62 citations97
US11591401B2Feb 28, 2023
Anti-CD28 compositions
XENCOR INC19 citations93
US9617348B2Apr 11, 2017
Compositions and methods for treating IgE-mediated disorders
XENCOR INC11 citations92
US7610156B2Oct 27, 2009
Methods for rational pegylation of proteins
XENCOR INC29 citations92
US7662367B2Feb 16, 2010
Pharmaceutical compositions for the treatment of TNF-α related disorders
XENCOR INC30 citations90
US7446174B2Nov 4, 2008
Protein based TNF-α variants for the treatment of TNF-α related disorders
XENCOR INC27 citations90
US7244823B2Jul 17, 2007
TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
XENCOR INC49 citations90
US11377477B2Jul 5, 2022
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
XENCOR INC7 citations85
US11358999B2Jun 14, 2022
IL-12 heterodimeric Fc-fusion proteins
XENCOR INC12 citations85
US11919958B2Mar 5, 2024
Anti-CD28 compositions
XENCOR INC9 citations84
US10738132B2Aug 11, 2020
Heterodimeric proteins
XENCOR INC9 citations84
US9902773B2Feb 27, 2018
Methods and compositions for inhibiting CD32b expressing cells
XENCOR INC4 citations84
US7930107B2Apr 19, 2011
Methods of generating variant proteins with increased host string content
XENCOR INC13 citations84
US7557190B2Jul 7, 2009
Optimized proteins that target Ep-CAM
XENCOR INC28 citations84
US9803020B2Oct 31, 2017
Optimized antibodies that target CD19
XENCOR INC5 citations83
CHAMBERLAIN AARON KEITH
8 patentsUS8394925B2Mar 12, 2013
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH63 citations99
US8088376B2Jan 3, 2012
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH191 citations99
US8883973B2Nov 11, 2014
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH57 citations98
US8338574B2Dec 25, 2012
FC variants with altered binding to FCRN
CHAMBERLAIN AARON KEITH32 citations96
US8324351B2Dec 4, 2012
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH30 citations96
US8318907B2Nov 27, 2012
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH27 citations96
US9200079B2Dec 1, 2015
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH28 citations92
US8852586B2Oct 7, 2014
Fc variants with altered binding to FcRn
CHAMBERLAIN AARON KEITH12 citations92
LAZAR GREGORY ALAN
8 patentsUS8388955B2Mar 5, 2013
Fc variants
LAZAR GREGORY ALAN104 citations99
US8188231B2May 29, 2012
Optimized FC variants
LAZAR GREGORY ALAN188 citations99
US8937158B2Jan 20, 2015
Fc variants with increased affinity for FcγRIIc
LAZAR GREGORY ALAN56 citations98
US8124731B2Feb 28, 2012
Optimized Fc variants and methods for their generation
LAZAR GREGORY ALAN55 citations98
US8093359B2Jan 10, 2012
Optimized Fc variants and methods for their generation
LAZAR GREGORY ALAN58 citations98
US8093357B2Jan 10, 2012
Optimized Fc variants and methods for their generation
LAZAR GREGORY ALAN51 citations98
US8734791B2May 27, 2014
Optimized fc variants and methods for their generation
LAZAR GREGORY ALAN19 citations92
US9574006B2Feb 21, 2017
Optimized anti-CD30 antibodies
LAZAR GREGORY ALAN5 citations83
CHU SEUNG YUP
5 patentsUS8063187B2Nov 22, 2011
Methods and compositions for inhibiting CD32B expressing cells
CHU SEUNG YUP130 citations98
US9394366B2Jul 19, 2016
Methods and compositions for inhibiting CD32B expressing cells
CHU SEUNG YUP16 citations92
US9260523B2Feb 16, 2016
Methods and compositions for inhibiting CD32b expressing cells
CHU SEUNG YUP9 citations92
US9079960B2Jul 14, 2015
Methods and compositions for inhibiting CD32B expressing cells
CHU SEUNG YUP12 citations92
US11447552B2Sep 20, 2022
Methods and compositions for inhibiting CD32B expressing cells
CHU SEUNG YUP3 citations83
BERNETT MATTHEW J
3 patentsUS8524867B2Sep 3, 2013
Optimized antibodies that target CD19
BERNETT MATTHEW J56 citations96
US8551485B2Oct 8, 2013
Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
BERNETT MATTHEW J45 citations93
US8314213B2Nov 20, 2012
Human equivalent monoclonal antibodies engineered from nonhuman variable regions
BERNETT MATTHEW J36 citations92
DESJARLAIS JOHN R
2 patentsPENN STATE RES FOUND
1 patentShowing the top 50 of 88 patents by PatentIndex Score.